⇚ Regimen KEYTRUDA® plus INLYTA® - for Renal Cancer Medical Name KEYTRUDA® (Pembrolizumab) plus INLYTA® (AXITINIB) - for advanced Renal Cell Carcinoma Cycles Given N/A Delivery Phases N/A Special Instructions Indicated for patients with metastatic Renal Cell Carcinoma regardless of PD-L1 tumor expression. Monitor closely for immune mediated end organ damage such as Pneumonitis, Colitis, Hepatitis and Nephritis. Continue KEYTRUDA® for a maximum of 24 months. INLYTA® is taken with or without food and should be swallowed whole with a glass of water. Given continuously until progression. Decrease the starting dose by approximately one half for patients with moderate hepatic impairment. References Rini BI, et al. NEJM 2019 - VIEW External References http://www.nejm.org/doi/full/10.1056/NEJMoa1816714 - VIEW Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration KEYTRUDA® (Pembrolizumab) IV 200 mg D1 q21 NSS 250 cc 60 minutes INLYTA® (Axitinib) PO 5 mg BID Daily N/A N/A N/A